Abstract:4542 Background: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to ICI by reducing immune-suppressive myeloid cells in metastatic ccRCC (Msaouel, Sci Transl Med 2022). ICI is the standard first-line (1L) treatment of metastatic ccRCC, and there is unmet need for improved treatment outcomes after progression on ICI. We hypothesized that sitravatinib plus nivolumab would revert an immunosuppressive tumor microenvironment (TME) to improve objective response rate (ORR) and survival in patients with metastatic ccRCC whose disease progressed on or after ICI. Methods: In this investigator-initiated, phase II, multicenter trial (NCT04904302), patients with progressive metastatic ccRCC after 1-2 lines of treatment were enrolled into three cohorts: Cohort A) progression on 1L nivolumab + ipilimumab, Cohort B) progression on 1L pembrolizumab + axitinib or 2L anti-PD-1 therapy after receiving 1L VEGF-targeted monotherapy, Cohort C) progression on 1L or 2L cabozantinib or lenvatinib +/- everolimus either before, after, or in combination with anti-PD-1 ICI. Starting dose of sitravatinib was 100 mg PO daily and nivolumab was 480 mg IV every 4 weeks. The co-primary endpoints were ORR [complete response (CR) + partial response (PR)] and disease control rate [DCR; CR, PR or stable disease (SD) at 24 weeks]. The study was designed to enroll 88 patients with an interim analysis for futility in each cohort using a BOP2 design, but it was terminated early due to discontinuation of sitravatinib development by the sponsor. Results: 14 patients were enrolled with 2 in cohort A, 6 in cohort B and 6 in cohort C. Most patients had IMDC intermediate risk disease (n=11, 78.6%), 7 patients had prior nephrectomy (50%), and sarcomatoid dedifferentiation was present in the tumors of 2 patients (7.1%). Across all cohorts, the ORR was 15.4% (2/13, 1 patient not evaluable) and DCR at 24 weeks was 35.7% (5/14). The 2 patients who experienced a PR were pre-treated with nivolumab + ipilimumab and pembrolizumab + axitinib. DCR at 24 months was 63% for Cohort A+B and 0% for Cohort C. After a median follow up of 11.9 months (mo), 10 patients had discontinued treatment (71.4%), all due to disease progression, and 6 patients had died (42.9%). Median progression free survival was 5.5 mo [ 95% CI 3.8 – not reached (NR)], and median overall survival was 13.3 mo (95% CI 8.77 – NR). Six patients (42.9%) experienced a grade 3-4 adverse event (AE) and 2 patients (14.3%) experienced an immune-mediated AE. Conclusions: In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. Clinical trial information: NCT04904302 .

NFS-11. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS

Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas

Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis

Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma

Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.

A Phase II Trial of Sitravatinib Plus Nivolumab after Progression on Prior Immune Checkpoint Inhibitor (ICI) in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc).

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis

Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma

Csig-19. Identification And Targeting Of Tumor Driver Schwann(Nf2Loss) Cells In Sporadic And Nf2-Related Vestibular Schwannomas

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis

A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)

A Systematic Review of Tumor Control and Hearing Preservation

A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.